Show simple item record

dc.date.accessioned2018-06-08T14:00:24Z
dc.date.issued2013-02
dc.identifier2
dc.identifier.citationANTICANCER RESEARCH, 2013, 33 pp. 371 - 377
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1766
dc.description.abstractBackground: Fascin-1 (FSCN1) plays an important role in cancer development and is associated with invasion and metastasis. Therefore, we explored the expression and localization of FSCN1 in epithelial ovarian cancer (EOC). Materials and Methods: Expression analysis was performed by immunohistochemistry of paraffin-embedded tumor samples from 89 patients with EOC. Staining intensity and the percentage of positively stained tumor cells were used to calculate an immunoreactive score of 0-12 (IRS). These results were correlated to clinical and pathological characteristics as well as to patient survival. Results: Negative (IRS=0), weak (IRS=0-2) and strong (IRS\ensuremath>2) expression of FSCN1 in EOC was found in 5 (5.6%), 30 (33.7%) and 54 (60.7%) tumor samples, respectively. There was a strong correlation of residual postoperative tumor of \ensuremath>1 cm with higher immunoexpression of FSCNI (p=0.04). Lower FSCN1 expression was associated with significantly poorer overall survival (p=0.02). Conclusion: FSCN1 is frequently expressed in primary EOC. Its prognostic impact and function remains inconclusive and should be further examined in larger trials.
dc.format.extent371 - 377
dc.languageeng
dc.language.isoeng
dc.titlePrognostic Impact of Fascin-1 (FSCN1) in Epithelial Ovarian Cancer
dc.typeJournal Article
rioxxterms.licenseref.startdate2013-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfANTICANCER RESEARCH
pubs.notesISI Document Delivery No.: 096SG Times Cited: 0 Cited Reference Count: 31 Hanker, Lars C. Karn, Thomas Holtrich, Uwe Graeser, Monika Becker, Sven Reinhard, Joscha Ruckhaeberle, Eugen Gevensleben, Heidrun Rody, Achim Held-Hecker foundation, Frankfurt, Germany We thank Samira Adel and Ekatherini Brinkmann for expert technical assistance. This work was supported by grants from Held-Hecker foundation, Frankfurt, Germany. Int inst anticancer research Athens keywords: Fascin-1 ovarian cancer expression prognosis immunohistochemistry actin-bundling protein mesenchymal transition breast-cancer expression invasiveness progression carcinoma tumors cells lung
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.volume33
pubs.embargo.termsNot known
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorGevensleben, Heidrunen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record